Mesoblast limited (OTCMKTS:MEOBF) shares fell 7% during mid-day trading on Monday . The company traded as low as $0.93 and last traded at $0.93. 1,000 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 2,662 shares. The stock had previously closed at $1.00.
The business’s 50 day moving average is $1.00.
COPYRIGHT VIOLATION WARNING: “Mesoblast (OTCMKTS:MEOBF) Shares Down 7%” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2019/06/17/mesoblast-otcmktsmeobf-shares-down-7.html.
About Mesoblast (OTCMKTS:MEOBF)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Story: Insider Trading
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.